Unsere Publikationen

Publikationen 2021

Kresken M, Korte-Berwanger M, Pfennigwerth N, Gatermann SG. In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany. J Global Antimicrob Resist. 2021;25: 337–338

Link

Gill CM, Kresken M, Seifert H, Nicolau DP. Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in Pseudomonas aeruginosa: Validation in a Multicenter German Cohort. Microb Drug Resist. Published Online:8 Jan 2021.

Link

Publikationen 2020

Gatermann S, Hamprecht A, Kresken M.
Die veränderte Definition von SIR bei Empfindlichkeitstestungen nach EUCAST.
Krankenhaushygiene up2date 2020; 15: 395–403

Link

Werner G, Neumann B, Weber RE, Kresken M, Wendt C, Bender JK. The VRE study group. Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci. Drug Resist Updat 53 (2020) 100732

Link

Kresken M, Pfeifer Y, Werner G. Temocillin susceptibility in Enterobacterales with an ESBL/AmpC-phenotype. Int J Antimicrob Agents. 2020; In Press, Journal Pre-proof, Available online 7 November 2020.

Link

Kresken M, Korte-Berwanger M, Gatermann SG, Pfeifer Y, Pfennigwerth N, Seifert H, Werner G. In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany. Int J Antimicrob Agents. 2020; 56:106128.

Link

Seifert H, Müller C, Stefanik D, Higgins PG, Miller A, Kresken M. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2020;75(9):2616–2621. https://doi.org/10.1093/jac/dkaa208folgende

Link

Gröschel MI, Meehan CJ, Barilar I, Diricks M, Gonzaga A, Steglich M, Conchillo-Solé O, Scherer IC, Mamat U, Luz CF, De Bruyne K, Utpatel C, Yero D, Gibert I, Daura X, Kampmeier S, Rahman NA, Kresken M, van der Werf TS, Alio I, Streit WR, Zhou K, Schwartz T, Rossen JWA, Farhat MR, Schaible UE, Nübel U, Rupp J, Steinmann J, Niemann S, Kohl TA. The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia. Nat Commun. 2020 Apr 27;11(1):2044. doi: 10.1038/s41467-020-15123-0.

Link

Kresken M, Körber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Seifert H; German Carbapenem Resistance Study Group. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany. Int J Antimicrob Agents. 2020; 55(6): 105959 doi: 10.1016/j.ijantimicag.2020.105959.

Link

Bodmann KF, Kresken M, Grabein B, Dohmen PM, Wilke M. Guideline Calculated parenteral initial therapy. Calculated parenteral initial treatment of bacterial infections: Introduction and antibiotics. GMS Infect Dis 2020; 8:Doc19 (20200326).

Link

Kresken M, Grabein B, Becker K, Straube E, Wichelhaus TA, Willinger B. Guideline Calculated parenteral initial therapy. Calculated parenteral initial treatment of bacterial infections: Microbiology. GMS Infect Dis 2020; 8:Doc18 (20200326)

Link